The Life Sciences team advised Galecto, Inc. (NASDAQ: GLTO) on its initial public offering of 5,666,667 shares of common stock at a public offering price of $15.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Galecto, are expected to be approximately $85.0 million. In addition, Galecto has granted the underwriters a 30-day option to purchase up to an additional 850,000 shares of common stock at the initial public offering price.
Galecto is a clinical-stage biotechnology company developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer.
The Goodwin team was led by Edwin O’Connor and included Ben Bertan, Kristen Kennedy, Tricia Hojo, Graham Defries, Andy Barton, Andre Amorim, Roger Cohen, Michael Brodowski, Daniel Karelitz, and Leon Peschel.
For more details, read the press release and articles in Endpoints and European Biotechnology.
Galecto is a clinical-stage biotechnology company developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer.
The Goodwin team was led by Edwin O’Connor and included Ben Bertan, Kristen Kennedy, Tricia Hojo, Graham Defries, Andy Barton, Andre Amorim, Roger Cohen, Michael Brodowski, Daniel Karelitz, and Leon Peschel.
For more details, read the press release and articles in Endpoints and European Biotechnology.